- Investing.com
Competitive Edge | Delve into Arcellx's differentiation strategy, focusing on anito-cel's efficacy and safety advantages over rival therapies in the evolving CAR-T landscape |
Financial Outlook | Analysts project sales growth from $110.3M in 2023 to $119.1M in 2024, with an average price target of $115, reflecting confidence in Arcellx's market position |
Market Dynamics | Explore the shifting landscape of multiple myeloma treatment, with CAR-T therapies projected to capture 30% of the market, presenting significant growth potential |
CAR-T Breakthrough | Arcellx's anito-cel shows promise in multiple myeloma treatment, with a 97% overall response rate and superior safety profile in clinical trials |
Metrics to compare | ACLX | Peers Peers - average of corresponding metrics from companies closely matching ACLX: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipACLXPeersSector |
|---|---|---|---|---|
P/E Ratio | −29.5x | 0.0x | −0.4x | |
PEG Ratio | 0.29 | 0.00 | 0.00 | |
Price / Book | 16.8x | 0.0x | 2.6x | |
Price / LTM Sales | 302.9x | 0.0x | 3.0x | |
Upside (Analyst Target) | −0.1% | 0.0% | 58.4% | |
Fair Value Upside | Unlock | 0.0% | 8.6% | Unlock |